The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hypertrophy (13%), and baseline LVEF <50% (12%). Based on the intent to treat analysis, overall response rate was 72%, including 28 patients in complete remission (complete remission rate, 56%), and 8 in partial remission (16%). At the end of treatment, grades 3 to 4 cardiac events were observed in 6 patients. No significant modifications from baseline values of LVEF were observed during treatment and follow-up.
| INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas, 1 typically affects elderly patients and can be cured in 60% to 70% of cases with the standard R-CHOP immunochemotherapy. 2, 3 Conventional anthracyclines are the active backbone of standard R-CHOP, but cardiotoxicity related to the cumulative dose may contraindicate or limit their use especially in patients with preexisting or concomitant cardiac disorders. 4 It has also been shown that cardiotoxicity was the predominant late chemotherapyrelated complication in long-term survivors with aggressive lymphoma. 5 However, cardiotoxicity data in patients with DLBCL are fragmentary and derive from relatively small studies, since patients older than 65, whose age-associated comorbidities may confer a higher risk of anthracycline cardiotoxicity, are often excluded from clinical trials. 6 Strategies to improve the cardiac safety of conventional anthracyclines include alterations of dosing schedules to modify pharmacokinetics, 7 use of other conventional anthracyclines that may be less cardiotoxic, administration of cardioprotective agents, 8 and administration of anthracyclines in liposome-encapsulated. In particular, the use of nonpegylated liposomal doxorubicin (NPLD) is associated with reduced myelosuppression, 9 reduced gastrointestinal toxicity, 10 and a reduced risk of cardiotoxicity 11 compared with standard formulations. A phase III randomized trial that compared NLPD and cyclophosphamide with doxorubicin and cyclophosphamide in patients with metastatic breast cancer revealed significantly reduced cardiotoxicity in the NLPD arm, without reducing the efficacy of therapy. 12 The toxicity and activity of NPLD when substituted for conventional doxorubicin in the CHOP regimen (so-called "R-COMP" regimen) have been evaluated also in the treatment of patients with newly diagnosed aggressive non-Hodgkin lymphomas, and the combination has been found to be an effective and relatively well tolerated regimen, 13, 14 even in patients with concurrent cardiac diseases or prior anthracyclines exposure. 15 On this background, we designed a multicenter, single-arm phase II trial addressing the activity and safety of the R-COMP combination as upfront treatment for patients with DLBCL who had concomitant or pre-existing cardiovascular disorders (CDs). circulatory, including high blood pressure, ischemic heart disease, and pulmonary hypertension; structural, including reduced LVEF, ventricu-Helsinki. The study protocol was approved by the ethic committees according to local rules. All patients gave their written informed consent to participate before study entry. Patient registration and data collection were realized using a dedicated web platform.
| Treatment
The The R-COMP was interrupted in case of grades 3 to 4 nonhematologic toxicity causing treatment delay of more than 3 weeks or for LVEF decrease of 20% from baseline or absolute 10 points in LEVF from baseline.
| Statistics
The primary end points of this phase II study were the complete remission rate (CRR) and the rate of cardiac events (CEs). Responses were assessed using the 2007 International Harmonization Project criteria. 17 Cardiac events were defined as LVEF decrease ≥20% from baseline or absolute LVEF <25% at the end of treatment or clinical evidence of heart failure. The coprimary end point analyses were performed for all eligible patients according to an intent to treat principle.
The study enrollment and monitoring was planned according to a Bayesian sequential analysis, considering a reference CRR of 65% 19 and CEs rate of 15%. 20 We planned to recruit a total of 55 patients, also considering a dropout rate of about 10% to reach 50 eligible patients. The a priori probability of CR and CEs were modeled by a beta distribution, with parameters B(1.32; 0.68) for efficacy and B(0.32; 1.68) for the safety. The trial was monitored by cohorts of 10 patients, and the study had to be interrupted if the observed response rate was lower than the reference CR, with a posterior probability greater than 95% (or more responsive with a posterior distribution lower than 0.05) or if the observed rate of CEs was higher than the ref- The secondary end points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
Adverse events were categorized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0).
3 | RESULTS
| Patients
Between November 2009 and October 2011, 51 patients were enrolled. One patient was subsequently excluded due to a violation of the inclusion criteria. Sixty CDs were identified at baseline; 2 and 3 concomitant CDs were described in 4 and 3 patients respectively.
Baseline patients characteristics are shown in Table 1 . Overall, 261 cycles of R-COMP were delivered. All but 68 cycles were administered on time: median delay was 3 days (range 1 to 28).
Dose reductions were adopted in 22 patients and in 68 cycles. The NPLD was reduced in 13 cases and in 37 cycles. The mean calculated dose intensity for all cycles of cyclophosphamide, NPLD, vincristine, and rituximab were 92.2%, 90.6%, 89.6%, and 95.6%, respectively.
Based on the intention to treat analysis, 28 patients achieved a CR at the end of therapy (56%; 95%CI, 41%-70%), and 36 patients had an objective response (ORR = 72%; 95%CI, 58% to 84%) ( Table 2) . As requested by the sequential Bayesian monitoring, the CR rate never fell outside activity boundaries ( Figure 1a in the Supporting information), thus the study achieved its main planned activity result.
The median follow-up was 33 months (range 1-61). Regarding the definition of PFS, 30 events were reported including 11 progressions, 12 relapses, and 7 deaths for causes unrelated with lymphoma. Median PFS was 17 months (95% CI; 9-NA months). Progression-free survival at 3 years was 38% (95%CI; 24%-51%) ( Figure 1A) .
Overall, 22 patients died, 6 during the treatment or within 3 months from treatment completion (2 due to lymphoma progression and one each due to acute renal failure, acute liver failure, cerebral hemorrhage, and pneumonia), and 16 during the follow-up phase (7 due to lymphoma progression, 2 each due to heart failure and severe infection, one each due to respiratory failure, cachexia not related with lymphoma, and lung cancer; in 2 cases, the cause of death was unknown). Median age of patients died for causes unrelated to lymphoma progression was 78 years (range 70-84). As a result, OS at 3 years was 50% (95%CI; 33%-65%) ( Figure 1B ).
| Safety
Safety analysis was available for all 50 patients and for 248 cycles.
Neutropenia was the most common hematologic event, with grades 3 to 4 toxicity occurring in 64% of patients. Excluding cardiac toxicity, grades 3 to 4 infections were the most common nonhematologic adverse events (6%) ( Table 3 ). Granulocyte colony-stimulating factor was used in 44 patients.
| Cardiac events
Ten patients experienced 11 CEs during treatment that were graded as 3 to 4 in 6 cases (12%). Grades 3 to 4 CEs included 3 cases of LVEF reduction ≥20% from baseline, 1 case each of congestive heart failure, angina, and atrial fibrillation. In 1 case, LVEF decrease was also associated with an increase of troponin level (Table 4) . Overall, study treatment was discontinued due to the occurrence of CEs in 6 cases, all occurred within the first 4 cycles (2 after cycle 3, and 3 after cycle Two patients died for congestive heart failure during the follow-up at 11 and 28 months from the last administration of R-COMP, respectively.
Considering LVEF monitoring, this was evaluated in 37 patients
with both assessments performed at baseline and end of therapy; in 13 cases, LVEF evaluation has not performed due to treatment interruption for toxicity (5) and for medical decision (2), due to unavailability of patient (4), progression of disease (1) , and loss to follow-up (1). At least 1 assessment during follow-up was performed in 27 cases. We observed a slight but not significant decrease from baseline to the end of treatment of the median LVEF (measured reduction −4.0%, P = .112) that remains stable during follow-up ( Figure 2) . A significant drop of LVEF was observed in individual cases.
We also analyzed the CE rates according to pretreatment CDs and observed a trend of higher rate of CEs in the patients affected by electrical disorders (30%) compared to the other 2 groups (circulatory and structural disorders, with 16% and 7% CEs respectively; P = .227).
Three CEs (1 increased troponin, 2 LVEF drop ≥20%) occurred among the 7 patients who were enrolled with a LVEF <50%.
| DISCUSSION
In the HEART01 study, we investigated the activity and the safety of the R-COMP regimen in which conventional doxorubicin was substituted with the same dose of NPLD for the treatment of patients with DLBCL who also had one or more concomitant or preexisting cardiac disorder. With 50 enrolled patients and with a median follow-up of 17 months, we were able to show a CR rate of 56%, a 3-year PFS of 38% and a 3-year OS of 50% with manageable adverse events that were mostly represented by severe neutropenia. Of note, the rate of CEs during therapy was 21% with a 10% rate of severe events but without any cardiac death during treatment. These activity and safety results fulfilled the initially planned study assumption and allow us to conclude this study with positive results and to consider R-COMP as a safe and active treatment option in patients with DLBCL and coexisting CDs.
Until now, NPLD has been evaluated in retrospective 21, 22 and in prospective studies [23] [24] [25] [26] [27] not selecting the patients with preexisting heart disease. The NPLD activity and safety profile in patients with contraindication to the use of conventional anthracyclines including cardiac disorders have been assessed only in 1 study. 15 More recently, 2 randomized studies compared the cardiotoxicity of NPLD with that of conventional doxorubicin in 2 independent series of patients with untreated DLBCL. 28, 29 Both studies included patients with normal cardiac function and were not able to show significant differences in the low observed rate of CEs between conventional doxorubicin and NPLD, also if safety signals were elevated in R-CHOP compared to R-COMP.
Of note, this prospective study evaluated the feasibility of a full dose chemoimmunotherapy regimen in a patient population that due to the presence of one or more CD would not have been considered eligible for a curative approach. The feasibility of the R-COMP regimen was confirmed with 76% of patients who were able to complete the planned therapy and with a very high mean dose intensity, also includ- and CDs as defined in our study or with contraindication to the use of anthracyclines represent a "hard to treat" population. 30, 31 In addition to the small sample size that is typical for a phase II study, our results could be influenced by the initial definition of the cardiac events that was based on a pragmatic approach and included most of the conditions that would have caused a reduction of the anthracycline dose if present. Considering the mechanism of anthracycline-induced cardiac toxicity, we acknowledge that the actual risk of doxorubicin induced cardiac toxicity can vary among patients with different cardiac conditions. In an exploratory analysis, we found that the CE rate was increasingly high comparing patients with electrical disorders to those with circulatory and structural disorders. In patients with structural disorders, the risk of experiencing CE is low.
In contrast, in patient with low baseline LVEF, the CE rate is still high also if an NPLD is administered in place of conventional doxorubicin.
Thus, the HEART01 study suggests that among patients with CD, the contraindication to the use of doxorubicin may change according to the quality of CD. In particular in patients at very high risk of CE, it is likely that the use of NPLD is not safe enough, and different strategies should be considered to preserve cardiac function and to allow the administration of oncologic therapy with curative intent. The use of doxorubicin-free regimens might represent a good option 30, 31 or, if doxorubicin containing regimens are used, prevention of anthracycline-induced cardiotoxicity could be considered before chemotherapy start. An accurate pretreatment cardiac evaluation could provide treatment of modifiable risks factors and optimize the cardiological therapy.
In conclusion, the HEART01 trial provides evidence of the feasibil- 
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